PRAME and neoplasm: PRAME expression has traditionally been observed in the nucleus and cytoplasm of tumor cells; therefore, immune-based strategies designed towards intracellular targets have been the treatment of choice, including acellular and cellular cancer vaccines and adoptive T cell therapy with autologous or TCR-engineered T cells.